TMS and Suicidal Thoughts: What Research Shows About Rapid Relief

TMS is not a treatment for a suicidal crisis, and no TMS device is FDA-cleared to treat suicidal thoughts. Research on whether TMS reduces suicidal ideation in depression is real but mixed: some sham-controlled trials show a faster or larger drop in suicidal thinking with active stimulation, while pooled analyses limited to randomized trials find effects that are small and not always statistically significant. Using TMS for suicidal ideation itself is therefore research-stage and off-label; it is cleared to treat depression, and suicidal thoughts often ease as depression lifts.

If you are thinking about suicide or are in crisis, call or text 988 (the 988 Suicide & Crisis Lifeline) or go to the nearest emergency room.

What the question really is

People ask about TMS and suicidal thoughts for two different reasons. Some are living with persistent, passive thoughts of not wanting to be alive while depression has not responded to medication, and they want to know whether TMS might help. Others have read headlines about "rapid relief" from accelerated protocols and wonder whether TMS could replace a hospital visit in an emergency. The answer to the first is "possibly, as part of depression treatment." The answer to the second is "no."

Studies in this area measure suicidal ideation with rating instruments such as the Beck Scale for Suicide Ideation or the single suicide item on the Hamilton Depression Rating Scale. A falling score is meaningful, but it is a measure of thoughts reported in a research setting. None of the trials below was designed or powered to show fewer suicide attempts or deaths.

Standard daily TMS: what the sham-controlled data show

The most informative early analysis pooled two randomized trials in treatment-resistant depression (156 patients) and looked at the suicide item of the Hamilton scale. Suicidal ideation resolved in 40.4% of patients given bilateral rTMS, 26.8% given left-sided rTMS and 18.8% given sham. Only the bilateral-versus-sham difference was statistically significant, and the authors found that only a modest part of the change in suicidal thinking tracked the change in overall depression. That last point is interesting: it hints that suicidal ideation may respond partly on its own track, though a secondary analysis cannot prove it.

Two meta-analyses then reached different conclusions. A 2022 review of 16 publications from a Toronto group found a decrease in suicidal ideation scores across randomized controlled trials that was small and not statistically significant (Hedges g 0.158, 95% CI -0.078 to 0.393), alongside a larger, significant drop in uncontrolled studies (g 0.692). A second 2022 meta-analysis that also searched Chinese-language databases pooled 8 randomized trials (566 patients) and found lower suicidal ideation scores with TMS than with control (SMD -0.415), while noting the limited quality and number of studies.

The gap between controlled and uncontrolled results matters. Suicidal ideation scores often fall with the extra attention, structure and hope that come with any new treatment, which is exactly what sham arms are designed to capture. Depression trials of TMS show a large sham response in general, with sham-treated patients improving substantially across 61 randomized trials.

Accelerated and high-dose protocols

The interest in "rapid relief" comes from protocols that pack many sessions into a few days. The table summarizes the studies that measured suicidal ideation directly.

Read together, these studies support feasibility and safety: high-dose schedules were tolerated, and none reported worsening suicidal ideation with active treatment. They do not establish a rapid anti-suicidal effect. Of the three sham-controlled studies, one found no difference from sham (Desmyter, 50 patients), one found only a non-significant trend (George, 41 patients), and one found a significant advantage at one week in patients who were all starting an antidepressant at the same time (Pan, 42 patients). The most striking response figure comes from an open-label study with no control group.

SAINT itself was cleared for depression, not for suicidality. Its pivotal sham-controlled data came from 29 treated patients in an early-stopped single-site trial, and FDA noted uncertainty about the adequacy of blinding. The details of that protocol are covered in our explainer on SAINT and Stanford Neuromodulation Therapy, and the wider evidence in accelerated TMS: protocols, evidence and FDA status.

Why TMS is not a crisis treatment

Several independent sources point the same way. A 2018 consensus statement from the National Network of Depression Centers and an APA task force advised that patients with "comorbid psychotic symptoms or acute suicidal ideation should be considered for other antidepressant treatments with established efficacy," naming ECT as the example. FDA's special-controls guidance for rTMS devices asks labeling to carry a bold warning about worsening depression or suicidality. New York State Medicaid states that TMS is "not first-line therapy for depression, nor is it indicated for acute suicidality." Commercial policies agree: Aetna lists active suicidality among conditions where TMS is not covered, and Optum lists acute suicidality and psychiatric emergencies as not medically necessary uses.

Timing is the practical reason. A standard acute course is daily, five days a week, and consensus guidance tells patients that 20 to 30 sessions over about six weeks will very likely be needed. Even the accelerated protocols require screening, scheduling, and in some cases an MRI, which is not how an emergency is handled.

When suicidal risk is acute, the options with established roles look different:

• Emergency evaluation and, where needed, hospital care.
• ECT, which the VA/DoD guideline rates "Strong for" in severe depression with severe suicidality, psychotic depression or catatonia. See TMS vs ECT for how the two compare.
• Esketamine (Spravato), a drug that is FDA-approved, with an oral antidepressant, for depressive symptoms in adults with major depression who have acute suicidal ideation or behavior. It is given only in certified settings with at least 2 hours of monitoring after each dose. TMS vs Spravato sets the two side by side.

Where TMS can reasonably fit

Many people with treatment-resistant depression have some degree of passive suicidal ideation without intent or a plan, and they are often appropriate outpatient TMS candidates after a careful evaluation. For them, TMS is a depression treatment, and any easing of suicidal thoughts is one of the outcomes to track rather than the reason for treatment.

A sound outpatient plan in this situation usually includes:

1. A structured suicide-risk assessment before the course starts. Optum's TMS policy, for example, expects one at admission.
2. A written safety plan, shared with the TMS team and, with permission, a family member or close friend.
3. Repeat measurement during the course with a validated scale, so that worsening is caught early rather than discovered at the end.
4. A clear agreement about what happens if thoughts intensify: who the patient calls, and when the course pauses for reassessment.
5. Continued therapy and medication management alongside stimulation, coordinated by one responsible physician. The case for that oversight is set out in who delivers TMS and why physician oversight matters.

Safety planning works alongside any treatment

A safety plan is a short, personal, written list that a patient builds with a clinician: warning signs, coping steps that can be done alone, people and places that help, who to contact for help, crisis lines, and ways to make the environment safer, such as limiting access to lethal means. It is low-tech, and unlike the TMS studies above it has been tested against suicidal behavior itself, not only against ideation scores.

In a large Veterans Health Administration study across 9 emergency departments, patients who received the Safety Planning Intervention plus follow-up phone calls had 45% fewer suicidal behaviors over 6 months than those receiving usual care (odds ratio 0.56), and were more likely to attend outpatient mental health care. That study was a cohort comparison rather than a randomized trial, but the finding is one reason safety planning is now standard practice, with or without TMS.

Questions worth asking before TMS when suicidal thoughts are part of the picture

• How will my suicide risk be assessed before treatment and during the course, and how often?
• Which scale will track my depression, and who reviews it each week?
• What happens if my thoughts get worse partway through: who do I call, and does treatment pause?
• Is TMS the right next step, or would ECT, esketamine or a medication change be more appropriate for how I am right now?
• How will the TMS team share information with my therapist and prescriber?

For a broader view of options after several medications have not worked, see treatment-resistant depression: every option compared, Dr. Lewis's overview of depression care, or the full TMS guide. The practice's current TMS information is on the TMS therapy page.

Frequently asked questions

Can TMS stop suicidal thoughts quickly?

Some high-dose and accelerated studies show suicidal ideation scores falling within days, but the sham-controlled studies are small and mixed, and the most dramatic figures come from open-label studies. TMS should not be relied on to resolve a crisis. If you are in danger now, call or text 988 or go to the nearest emergency room.

Will a TMS clinic treat me if I have suicidal thoughts?

Many people with passive thoughts of death and treatment-resistant depression are evaluated for outpatient TMS. Active suicidal intent, a plan or a recent attempt usually points toward a higher level of care first, and several insurers exclude active suicidality from TMS coverage.

Can TMS make suicidal thoughts worse?

The studies that measured suicidal ideation did not report worsening with active TMS compared with sham. FDA still asks device labeling to warn about worsening depression or suicidality, which is why symptoms should be checked throughout a course.

Is Spravato better than TMS for suicidal thoughts?

They are approved or cleared for different things. Spravato is an FDA-approved drug for depressive symptoms in adults with major depression and acute suicidal ideation or behavior, used with an oral antidepressant and given under monitoring. No TMS device is cleared for suicidal ideation.

Should my safety plan change during TMS?

Review it at the start of the course and whenever symptoms shift. Make sure the TMS team knows who to contact and what steps you have agreed on.

Sources

1. The Effect of Repetitive Transcranial Magnetic Stimulation on Suicidal Ideation in Treatment-Resistant Depression: A Meta-Analysis. Journal of Clinical Psychiatry, 2022. pubmed.ncbi.nlm.nih.gov
2. Bilateral Repetitive Transcranial Magnetic Stimulation Decreases Suicidal Ideation in Depression. Journal of Clinical Psychiatry, 2018. pubmed.ncbi.nlm.nih.gov
3. Efficacy of Transcranial Magnetic Stimulation for Reducing Suicidal Ideation in Depression: A Meta-Analysis. Frontiers in Psychiatry, 2022. pubmed.ncbi.nlm.nih.gov
4. A two-site pilot randomized 3 day trial of high dose left prefrontal repetitive transcranial magnetic stimulation (rTMS) for suicidal inpatients. Brain Stimulation, 2014. pubmed.ncbi.nlm.nih.gov
5. Accelerated Intermittent Theta Burst Stimulation for Suicide Risk in Therapy-Resistant Depressed Patients: A Randomized, Sham-Controlled Trial. Frontiers in Human Neuroscience, 2016. pubmed.ncbi.nlm.nih.gov
6. Neuronavigation-Guided rTMS for the Treatment of Depressive Patients With Suicidal Ideation: A Double-Blind, Randomized, Sham-Controlled Trial. Clinical Pharmacology & Therapeutics, 2020. pubmed.ncbi.nlm.nih.gov
7. Targeting suicidal ideation in major depressive disorder with MRI-navigated Stanford accelerated intelligent neuromodulation therapy. Translational Psychiatry, 2024. pubmed.ncbi.nlm.nih.gov
8. Comparison of the Safety Planning Intervention With Follow-up vs Usual Care of Suicidal Patients Treated in the Emergency Department. JAMA Psychiatry, 2018. pubmed.ncbi.nlm.nih.gov
9. A systematic review and meta-analysis on placebo response to repetitive transcranial magnetic stimulation for depression trials. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 2018. pubmed.ncbi.nlm.nih.gov
10. 510(k) Summary K220177: Magnus Neuromodulation System with SAINT Technology. U.S. FDA, 2022. accessdata.fda.gov
11. Consensus Recommendations for the Clinical Application of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Depression. Journal of Clinical Psychiatry, 2018. pmc.ncbi.nlm.nih.gov
12. Class II Special Controls Guidance Document: Repetitive Transcranial Magnetic Stimulation (rTMS) Systems. U.S. FDA, 2011. fda.gov
13. New York State Medicaid Coverage of Therapeutic Transcranial Magnetic Stimulation (Medicaid Update, July 2025). NYS Department of Health, 2025. healthweb-back.health.ny.gov
14. Transcranial Magnetic Stimulation and Cranial Electrical Stimulation (Clinical Policy Bulletin 0469). Aetna, 2026. aetna.com
15. Behavioral Clinical Policy: Transcranial Magnetic Stimulation. Optum Behavioral Health Solutions, 2026. providerexpress.com
16. VA/DoD Clinical Practice Guideline for the Management of Major Depressive Disorder. Department of Veterans Affairs / Department of Defense, 2022. healthquality.va.gov
17. Drugs@FDA: NDA 211243 SPRAVATO. U.S. FDA, 2020. accessdata.fda.gov
18. SPRAVATO (esketamine) nasal spray, CIII - Prescribing Information. Janssen / DailyMed, 2026. dailymed.nlm.nih.gov
19. Premarket Notification 510(k). U.S. FDA, 2026. fda.gov

Educational information, not medical advice. Whether TMS or any treatment fits you is a decision to make with a psychiatrist who knows your history.